Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what recent assessments has the department made of the potential benefits of extending the meningitis B vaccination programme to teenagers.

Meningococcal disease is an uncommon but serious disease caused by meningococcal bacteria. The MenACWY vaccine offers good protection against several strains of meningococcal disease and is routinely offered to teenagers in school years 9 and 10. However, it does not protect against all strains. Other strains, such as Meningitis B (MenB), can circulate among young adults. From 2015, the MenB vaccine has been available on the National Health Service as part of routine childhood immunisations, but most students would not be vaccinated.

Decisions on vaccination programmes follow independent expert advice from the Joint Committee on Vaccination and Immunisation (JCVI). The JCVI does not currently recommend a routine MenB booster vaccination for adolescents and young adults, however the JCVI routinely reviews new evidence as it emerges and my Rt Hon. Friend, the Secretary of State for Health and Social Care, will ask them to reexamine eligibility for meningitis vaccines.

The importance of raising awareness in parents, teenagers and other adults about the signs and symptoms of meningitis remains key. There are a range of resources developed by the UK Health Security Agency, co-branded with the National Health Service, that set out these key messages and their importance, such as the teenage guide to immunisation.